Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.hester.in | |
Market Cap | 1,527.07 Cr. | |
Enterprise Value(EV) | 1,769.96 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 35.05 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 50.86 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.44 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 322.40 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 5.53 | Calculated using Price: 1,782.95 |
Dividend Yield | 0.56 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.85 Cr. | 8,506,865 Shares |
FaceValue | 10 | |
Company Profile | ||
Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008. |
1 Day |
|
-0.30% |
1 Week |
|
-0.83% |
1 Month |
|
-0.77% |
3 Month |
|
-10.47% |
6 Month |
|
-21.80% |
1 Year |
|
-28.39% |
2 Year |
|
+2.36% |
5 Year |
|
+17.07% |
10 Year |
|
+1293.47% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 12.88 | 16.73 | 20.56 | 20.38 | 17.57 | 25.59 | 16.38 | 16.16 | 16.00 | |
Return on Capital Employed (%) | 17.78 | 17.26 | 18.98 | 19.75 | 20.20 | 26.64 | 16.53 | 17.33 | 14.02 | |
Return on Assets (%) | 6.89 | 8.84 | 11.08 | 11.43 | 10.10 | 14.97 | 9.04 | 8.70 | 8.03 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 75 | 85 | 102 | 122 | 141 | 177 | 201 | 228 | 260 | 264 | |
Non Curr. Liab. | 20 | 38 | 41 | 48 | 44 | 70 | 97 | 114 | 198 | 244 | |
Curr. Liab. | 45 | 35 | 38 | 38 | 55 | 49 | 83 | 61 | 97 | 109 | |
Minority Int. | 1 | 3 | 5 | 5 | 4 | 4 | 5 | 8 | 7 | 7 | |
Equity & Liab. | 142 | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 624 | |
Non Curr. Assets | 85 | 100 | 112 | 133 | 146 | 158 | 227 | 250 | 367 | 418 | |
Curr. Assets | 57 | 60 | 74 | 80 | 98 | 142 | 159 | 162 | 195 | 206 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 142 | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 624 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 69 | 90 | 101 | 123 | 136 | 178 | 183 | 214 | 235 | 255 | |
Other Income | 1 | 0 | 1 | 0 | 3 | 7 | 6 | 5 | 14 | 19 | |
Total Income | 70 | 90 | 102 | 124 | 138 | 185 | 190 | 219 | 249 | 274 | |
Total Expenditure | -45 | -65 | -68 | -82 | -89 | -110 | -128 | -146 | -175 | -206 | |
PBIDT | 25 | 26 | 34 | 41 | 50 | 75 | 62 | 73 | 74 | 68 | |
Interest | -6 | -5 | -4 | -4 | -4 | -7 | -7 | -7 | -4 | -9 | |
Depreciation | -5 | -6 | -6 | -7 | -10 | -12 | -13 | -13 | -17 | -20 | |
Taxation | -4 | -5 | -6 | -8 | -13 | -16 | -10 | -15 | -14 | -12 | |
Exceptional Items | 3 | -3 | |||||||||
PAT | 9 | 13 | 19 | 23 | 23 | 41 | 31 | 35 | 39 | 27 | |
Minority Interest | 0 | 0 | 0 | 1 | 3 | 1 | -2 | 0 | 0 | -2 | |
Share Associate | 0 | 5 | |||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 9 | 14 | 19 | 24 | 26 | 42 | 29 | 34 | 39 | 30 | |
Adjusted EPS | 11 | 16 | 23 | 28 | 30 | 49 | 34 | 40 | 46 | 35 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 12 | 9 | 20 | 19 | 35 | 38 | 47 | 37 | 58 | 9 | |
Cash Fr. Inv. | -23 | -15 | -21 | -13 | -30 | -26 | -22 | -74 | -38 | -117 | |
Cash Fr. Finan. | 10 | 7 | 7 | -7 | 2 | -11 | 3 | 19 | -18 | 112 | |
Net Change | -1 | 2 | 5 | -1 | 6 | 1 | 28 | -19 | 1 | 4 | |
Cash & Cash Eqvt | 2 | 4 | 6 | 5 | 11 | 12 | 41 | 24 | 21 | 25 |
Thu, 02 Feb 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Pursuant to Regulations 30 and 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached the transcript of the earnings conference call held by the management of the Company with investors on Tuesday 31 January 2023 at 2:00 p.m. (IST) to discuss the unaudited financial results for the quarter and nine months ended 31 December 2022. This is for your information and records. |
Wed, 01 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby submit a copy of the published extract of consolidated unaudited financial results for the quarter and nine months ended 31 December 2022 along with information on standalone financial results.The same was published on Wednesday 1 February 2023 in the Ahmedabad edition of Financial Express (English) and Financial Express (Gujarati). |
Tue, 31 Jan 2023
Financial Results For Q3 & 9M FY23 Financial Results for Q3 & 9M FY23 |
Thu, 02 Feb 2023 |
|
|
|
|
|